DSP Healthcare Fund Review – 99% Unbiased (2026 Update)

Last Updated on April 5, 2026 by Hemant Beniwal

When DSP launched their Healthcare Fund in November 2018 — their first product after the BlackRock divorce — I wrote that I was disappointed. Not because AMCs launch NFOs in bull markets (they all do), but because DSP had been making genuinely progressive decisions, and launching a sector fund in a hot space felt regressive.

Seven years later, was I right?

Well, the fund delivered ~16.9% CAGR over 5 years (Regular plan) — which sounds great until you realise that a plain Nifty 50 index fund delivered similar returns with far less sector concentration risk. And in the last 1 year? The fund is in the red.

Let me walk you through what this fund actually does, how it has performed with real data, and whether it deserves a place in your portfolio in 2026.

DSP Healthcare Fund — Key Features

What Makes This Fund Different — The International Healthcare Angle

Unlike pure Indian pharma funds, DSP Healthcare Fund allocates up to 25% in US healthcare stocks. Think of it like this: you’re betting on Indian hospitals and generic drug makers, but you also have a small window into US biotech and big pharma companies.

In theory, this diversification across geographies should reduce risk. In practice, when both Indian and US healthcare sectors move together (as they did during COVID and post-COVID), the “diversification benefit” shrinks.

It’s not a pure sector fund — it’s a theme fund. But that distinction is like saying “it’s not a sword, it’s a very sharp knife.” For the average investor, the concentration risk is still dangerously high.

7-Year Performance — The Numbers Don’t Lie

The fund launched at ₹10 NAV in November 2018. Here’s what happened:

Now here’s the question that actually matters: how many investors who entered this fund actually captured those returns?

In my experience — very few. Here’s why.

The “Field of Dreams” Problem — Why Sector Fund Investors Lose Money

There’s a classic movie about an Iowa corn farmer who hears a voice telling him to build a baseball field in his farm. “If you build it, he will come.”

Our mutual fund industry works the same way. AMCs launch fancy sectoral products when a sector is already generating superior returns. Money floods in at the peak. Then the cycle turns. Investors panic and exit at the bottom.

I’ve seen this movie play out in real life — multiple times. Let me share a pattern I’ve witnessed across 18+ years of financial planning:

Ramesh (name changed), a client from Bengaluru, invested ₹5 lakh in a pharma fund in early 2015 when pharma stocks were on fire. By 2018, his ₹5 lakh had become ₹3.8 lakh. He exited in frustration — right before the sector started recovering. If he had been in a simple flexicap fund instead, his ₹5 lakh would have been ₹7.5 lakh+ by 2021.

The problem isn’t the fund. The problem is investor behaviour in concentrated bets. You enter when the sector is hot (buying high), you panic when it underperforms (selling low), and you miss the recovery because you’ve already moved to the next “hot” sector.

Why AMCs Launch Sector Funds When They Do

Let me be blunt: sector fund launches are not timed for your benefit. They’re timed for AUM collection.

No pharma fund was launched between 2006 and 2012 — when pharma was actually cheap. Fund houses launched pharma/healthcare NFOs when the sector was already in the headlines. DSP Healthcare Fund launched in November 2018, after the BSE Healthcare index had already given 300%+ returns in the preceding decade.

This isn’t unique to DSP. Every AMC does it. The pattern is universal: launch sector fund → hot sector attracts money → sector corrects → investors exit in losses → AMC collects fees throughout.

I wrote about this exact pattern in our ICICI Prudential India Opportunities Fund review — the cycle repeats with different sector labels.

Our Practice’s Experience with Pharma Sector Funds

In the interest of full disclosure: we did allocate small positions (5-8% of equity) to what was then Reliance Pharma Fund (now Nippon India Pharma Fund) for a few clients in 2009-2010, when the risk-reward was genuinely attractive. We exited by end of 2014 and early 2015 — that added some alpha to those specific portfolios.

But we entered when the sector was out of favour, allocated a small percentage, and had a clear exit plan. That’s the only way sector funds work — and most retail investors don’t operate this way.

Healthcare Sector — The Bull Case vs Reality

The healthcare sector bulls will tell you:

• India’s healthcare spending is growing (true — projected to reach $372 billion by 2027)
• Ageing population drives demand (true)
• Government schemes like Ayushman Bharat expand access (true)
• India is the “pharmacy of the world” (partially true — generics, yes; innovation, not yet)

All of this is real. But here’s the uncomfortable truth: a good sector doesn’t automatically make a good investment.

Infrastructure was a “great story” in 2007. IT was a “can’t lose” sector in 1999. Real estate was “always going up” in 2012. The story was right. The timing was wrong. And timing is everything in sector funds because you can’t diversify away the sector-specific risk.

I’ve written about how structured products exploit the same “great story, wrong timing” pattern — the psychology is identical.

Should You Invest in DSP Healthcare Fund in 2026?

My stance hasn’t changed in 7 years, and the data has only reinforced it:

For most investors (90%+): No. Stick with diversified equity funds — flexi-cap, large-cap, or index funds. These will automatically allocate to healthcare stocks when valuations are attractive. You get the sector exposure without the concentration risk.

For experienced investors with a clear thesis: If you genuinely believe healthcare will outperform the broader market over the next 5-7 years, AND you can stomach 30-40% drawdowns without panicking, AND you will limit allocation to 5-10% of your equity portfolio — then DSP Healthcare Fund is one of the better options in this space, particularly because of the international diversification angle.

But honestly? In 18+ years of practice, I’ve met maybe 5 clients who could actually hold a sector fund through its full cycle without panicking. The odds are not in your favour.

Why “99% Unbiased”?

Because we’re all blinded by our biases — and the person who claims to be 100% unbiased is the one you should trust the least. I’ve been skeptical of sector funds for over 15 years. That’s a bias. But it’s one that has saved my clients a lot of money.

Diversification isn’t boring. It’s how you actually keep your money.

The best investment isn’t the one that gives the highest return. It’s the one you can hold through the cycle without losing sleep.